Table 4.
Study outcomes as a function of the de-escalation therapy status
| Primary end point | De-escalation therapy (n = 58) | No de-escalation therapy (n = 85) | p-value |
|---|---|---|---|
| Death from all causes at 15 days, n (%) | 3/58 (5.1) | 27/85 (31.7) | < 0.05 |
| Quantitative tracheal aspirate | 1/17 (5.8) | 22/64 (34.3) | 0.02 |
| Bronchoalveolar lavage | 2/41 (4.8) | 5/21 (23.8) | 0.02 |
| Death from all causes at 28 days, n (%) | 7/58 (12) | 37/85 (43.5) | < 0.05 |
| Quantitative tracheal aspirate | 2/17 (11.6) | 29/64 (45.3) | 0.01 |
| Bronchoalveolar lavage | 5/41 (12.1) | 8/21 (38) | 0.01 |
| Intensive care unit duration of stay, days (SD) | 17.2 (1.2) | 22.7 (6.3) | < 0.05 |
| Quantitative tracheal aspirate | 17.2 (1.6) | 22.4 (6.4) | < 0.05 |
| Bronchoalveolar lavage | 17.2 (1.1) | 23.2 (6) | < 0.05 |
| Hospital duration of stay, days (SD) | 23.7 (2.8) | 29.8 (11.16) | < 0.05 |
| Quantitative tracheal aspirate | 23.1 (4.4) | 29.9 (11.16) | < 0.05 |
| Bronchoalveolar lavage | 23.8 (2.4) | 29.8 (11.4) | 0.02 |